Filter content by tags:
Non-drug options in oligometastatic RCC

Speaker: Panu Jaakkola
Date: 1st December 2023
Tags: Nordic RCC Summit 2023, Treatment landscape

Approaches to treatment of oligoprogressive disease, Patient case and discussion

Speaker: Jesper Andreas Palshof
Date: 1st December 2023
Tags: Nordic RCC Summit 2023, Treatment landscape

nccRCC – Should we change our practice?

Speaker: Katarina Puco
Date: 1st December 2023
Tags: Nordic RCC Summit 2023, Treatment landscape

1st line therapy for metastatic renal cell carcinoma

Speaker: Prof. Dr. Jonas Busch, Department of Urology, Berlin Vivantes Klinikum Am Urban & Im Friedrichshain
Date: 25 May 2023
Tags: Treatment landscape

IO/IO vs IO/TKI in frontline setting mRCC – Pros and Cons

Speaker: Daniel Heinrich Senior Consultant Clinical Oncologist Department of Radiotherapy and Oncology Innlandet Hospital Trust, Norway
Date: 10 May 2023
Tags: Treatment landscape

Case experiences with combination therapy with cabozantinib + nivolumab as first-line treatment

Speaker: Interview with Professor Viktor Grünwald.
Date: 2 August 2022
Tags: Cabo-nivo combination, Treatment landscape, First line systemic therapy

Long-Term effectiveness results of CheckMate-9ER

Speaker: Interview with Professor Toni K. Choueiri.
Date: 2 August 2022
Tags: Cabo-nivo combination, Treatment landscape, First line systemic therapy

First-line combination treatments available for renal cell carcinoma

Speaker: Interview with Professor Sumanta Kumar Pal.
Date: 2 August 2022
Tags: Treatment landscape, First line systemic therapy

Nivolumab + Cabozantinib for the treatment of advanced Renal-Cell Carcinoma in 1L

IPSEN and Bristol Myers Squibb webinar.
Speaker: Petri Bono, Viktor Grünwald, MD and Thomas Powles MBBS, MRCP, MD.
Date: 12 October 2021
Tags: Cabo-nivo combination, Treatment landscape, First line systemic therapy

Rationale for combinations with CPI

Speaker: Katarina Puco, Senior Consultant Oncologist. Lovisenberg Diaconal Hospital Norway.
Date: 9 September 2021
Tags: Treatment landscape, First line systemic therapy